{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T05:39:40Z","timestamp":1761197980227,"version":"3.44.0"},"reference-count":19,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,7,26]],"date-time":"2021-07-26T00:00:00Z","timestamp":1627257600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transplantation Proceedings"],"published-print":{"date-parts":[[2021,9]]},"DOI":"10.1016\/j.transproceed.2021.07.031","type":"journal-article","created":{"date-parts":[[2021,8,25]],"date-time":"2021-08-25T01:24:11Z","timestamp":1629854651000},"page":"2252-2260","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Selection of More Vulnerable Patients for Cytomegalovirus Infection in Renal Transplant Recipients With Antithymocyte Globulin Induction Therapy: An Analysis of Risk Factors and Cell-Mediated Immunity"],"prefix":"10.1016","volume":"53","author":[{"given":"Kang-woong","family":"Jun","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1459-8843","authenticated-orcid":false,"given":"Ji-hyang","family":"Lim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeong-kye","family":"Hwang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sun-cheol","family":"Park","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ji-il","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sang-seop","family":"Yun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6190-085X","authenticated-orcid":false,"given":"Mi-hyeong","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.transproceed.2021.07.031_bib0001","doi-asserted-by":"crossref","first-page":"1967","DOI":"10.1056\/NEJMoa060068","article-title":"Rabbit antithymocyte globulin versus basiliximab in renal transplantation","volume":"355","author":"Brennan","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.transproceed.2021.07.031_bib0002","first-page":"820","article-title":"Increased risk of rejection after basiliximab induction in sensitized kidney transplant recipients without pre-existing donor-specific antibodies \u2013 a retrospective study","volume":"32","author":"Goumard","year":"2019","journal-title":"Transpl Int"},{"key":"10.1016\/j.transproceed.2021.07.031_bib0003","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.1111\/ajt.13191","article-title":"Daclizumab versus rabbit antithymocyte globulin in high-risk renal transplants: five-year follow-up of a randomized study","volume":"15","author":"Hellemans","year":"2015","journal-title":"Am J Transplant"},{"key":"10.1016\/j.transproceed.2021.07.031_bib0004","article-title":"Polyclonal and monoclonal antibodies for induction therapy in kidney transplant recipients","volume":"1","author":"Hill","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.transproceed.2021.07.031_bib0005","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1016\/j.transproceed.2011.01.035","article-title":"Low-dose rabbit antithymocyte globulin versus basiliximab induction therapy in low-risk renal transplant recipients: 8-year follow-up","volume":"43","author":"Laftavi","year":"2011","journal-title":"Transplant Proc"},{"key":"10.1016\/j.transproceed.2021.07.031_bib0006","doi-asserted-by":"crossref","first-page":"2611","DOI":"10.1016\/j.transproceed.2019.02.061","article-title":"Effectiveness of thymoglobulin induction therapy in kidney transplant from deceased donor with mild to moderate acute kidney injury","volume":"51","author":"Lee","year":"2019","journal-title":"Transplant Proc"},{"key":"10.1016\/j.transproceed.2021.07.031_bib0007","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1097\/TP.0000000000002804","article-title":"Induction therapy in elderly kidney transplant recipients with low immunological risk","volume":"104","author":"Masset","year":"2020","journal-title":"Transplantation"},{"key":"10.1016\/j.transproceed.2021.07.031_bib0008","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1097\/TP.0000000000002191","article-title":"The Third International Consensus Guidelines on the Management of Cytomegalovirus in Solid-organ Transplantation","volume":"102","author":"Kotton","year":"2018","journal-title":"Transplantation"},{"key":"10.1016\/j.transproceed.2021.07.031_bib0009","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1034\/j.1600-6143.3.s4.11.x","article-title":"Expanded criteria donors for kidney transplantation","volume":"3","author":"Metzger","year":"2003","journal-title":"Am J Transplant"},{"key":"10.1016\/j.transproceed.2021.07.031_bib0010","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1038\/nrneph.2011.14","article-title":"Classification and staging of acute kidney injury: beyond the RIFLE and AKIN criteria","volume":"7","author":"Ricci","year":"2011","journal-title":"Nat Rev Nephrol"},{"key":"10.1016\/j.transproceed.2021.07.031_bib0011","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1038\/nrneph.2013.44","article-title":"Immune cell dysfunction and inflammation in end-stage renal disease","volume":"9","author":"Betjes","year":"2013","journal-title":"Nat Rev Nephrol"},{"key":"10.1016\/j.transproceed.2021.07.031_bib0012","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1007\/s11934-014-0471-9","article-title":"Chronic kidney disease and premature ageing of the adaptive immune response","volume":"16","author":"Betjes","year":"2015","journal-title":"Curr Urol Rep"},{"key":"10.1016\/j.transproceed.2021.07.031_bib0013","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0112361","article-title":"Average values and racial differences of neutrophil lymphocyte ratio among a nationally representative sample of United States subjects","volume":"9","author":"Azab","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.transproceed.2021.07.031_bib0014","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/s13104-016-2335-5","article-title":"What is the normal value of the neutrophil-to-lymphocyte ratio?","volume":"10","author":"Forget","year":"2017","journal-title":"BMC Res Notes"},{"key":"10.1016\/j.transproceed.2021.07.031_bib0015","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1111\/tri.12321","article-title":"Kinetics of peripheral blood lymphocyte subpopulations predicts the occurrence of opportunistic infection after kidney transplantation","volume":"27","author":"Fernandez-Ruiz","year":"2014","journal-title":"Transpl Int"},{"key":"10.1016\/j.transproceed.2021.07.031_bib0016","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1002\/lt.23991","article-title":"Pretransplant lymphopenia is a novel prognostic factor in cytomegalovirus and noncytomegalovirus invasive infections after liver transplantation","volume":"20","author":"Nierenberg","year":"2014","journal-title":"Liver Transpl"},{"key":"10.1016\/j.transproceed.2021.07.031_bib0017","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1086\/654931","volume":"202","author":"Abate","year":"2010","journal-title":"J Infect Dis"},{"key":"10.1016\/j.transproceed.2021.07.031_bib0018","first-page":"1","article-title":"Monitoring of CMV-specific cell-mediated immunity with a commercial ELISA-based interferon-gamma release assay in kidney transplant recipients treated with antithymocyte globulin","volume":"00","author":"Fernandez-Ruiz","year":"2020","journal-title":"Am J Transplant"},{"key":"10.1016\/j.transproceed.2021.07.031_bib0019","doi-asserted-by":"crossref","first-page":"2505","DOI":"10.1111\/ajt.15315","article-title":"A prospective multicenter observational study of cell-mediated immunity as a predictor for cytomegalovirus infection in kidney transplant recipients","volume":"19","author":"Kumar","year":"2019","journal-title":"Am J Transplant"}],"container-title":["Transplantation Proceedings"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0041134521004991?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0041134521004991?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T21:39:11Z","timestamp":1758577151000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0041134521004991"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9]]},"references-count":19,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2021,9]]}},"alternative-id":["S0041134521004991"],"URL":"https:\/\/doi.org\/10.1016\/j.transproceed.2021.07.031","relation":{},"ISSN":["0041-1345"],"issn-type":[{"type":"print","value":"0041-1345"}],"subject":[],"published":{"date-parts":[[2021,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Selection of More Vulnerable Patients for Cytomegalovirus Infection in Renal Transplant Recipients With Antithymocyte Globulin Induction Therapy: An Analysis of Risk Factors and Cell-Mediated Immunity","name":"articletitle","label":"Article Title"},{"value":"Transplantation Proceedings","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.transproceed.2021.07.031","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}